Date: 2017-04-11
Type of information: Construction of new premises
Compound: new production plant in Prevalje (Slovenia)
Company: Novartis (Switzerland)
Therapeutic area:
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: • On April 11, 2017, Novartis and Sandoz/Lek announced that a foundation stone for the new production plant for the broad-spectrum antibiotic, amoxicillin-clavulanic acid, was laid at the Novartis site in Prevalje, in the presence of Miro Cerar, PhD, Prime Minister of the Republic of Slovenia. The value of the first investment stage is € 85 million, starting in 2017 with expected completion by 2019. The total value of the investment will amount to € 105 million and will be the largest Novartis investment in Slovenia to date. With this investment in new facilities, Novartis is consolidating its position as one of the most important employers in the Carinthia region. By 2019, around 150 new employees are expected to join the existing 246 employees at the Prevalje site, more than doubling the number of employees over only six years (2013/ 2019 index 223). These are mainly jobs that bring high added value and the emphasis is on recruiting employees locally. Since 2003, Novartis has invested more than € 1.9 billion in Slovenia.
Financial terms:
Latest news:
